@article{PAR00003606,
  title = {{E}valuation of transmitted {HIV} drug resistance among recently-infected antenatal clinic attendees in four {C}entral {A}frican countries},
  author = {{A}ghokeng {F}obang, {A}velin and {V}ergne, {L}aurence and {M}poudi {N}gol{\'e}, {E}. and {M}bangue, {M}. and {D}eoudje, {N}. and {M}okondji, {E}. and {N}ambei, {W}. {S}. and {P}eyou-{N}di, {M}. {M}. and {M}oka, {J}.{J}.{L}. and {D}elaporte, {E}ric and {P}eeters, {M}artine},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {T}he rapid expansion of antiretroviral treatment in resource-limited settings is raising concerns regarding the emergence and transmission of {HIV} drug resistance ({HIVDR}). {W}e evaluated the extent of transmission of drug-resistant {HIV} strains in four {C}entral {A}frican countries: the {R}epublic of {C}ongo, {C}entral {A}frican {R}epublic, {C}had and {C}ameroon. {M}ethods: {T}he {W}orld {H}ealth {O}rganization ({WHO}) {HIVDR} threshold survey was implemented in major treatment areas in each country. {P}regnant women who were aged <25 years, who were at first pregnancy and who were {HIV} type-1-positive were enrolled at each site in 2006-2007 for genotyping. {HIVDR} prevalence was categorized using the {WHO} threshold survey binomial sequential sampling method. {R}esults: {T}he prevalence of {HIVDR} in {B}razzaville and {B}angui sites could not be classified because the eligible sample number was not reached. {HIVDR} prevalence was low (<5%) in {N}'{D}jamena for all drug classes. {I}n {Y}aounde, we found one individual with the {D}67{D}/{N} mutation and two with {K}103{N}. {HIVDIR} prevalence was categorized as low (<5%) for protease inhibitors ({P}is) and nucleoside reverse trainscriptase inhibitors ({NRTI}s), and moderate (>= 5-<= 5%) for non-{NRTI}s ({NNRTI}s). {HIVDR} prevalence in {D}ouala was low for {P}is and {NNRTI}s, and moderate for {NRTI}s as we identified one individual with {M}184{V} plus {K}101{E} plus {G}190{A} mutations and a second with {D}67{D}/{N}. {C}onclusions: {T}he moderate {HIVDR} prevalence found in {Y}aounde and {D}ouala indicate that efforts should be made in {C}ameroon to prevent {HIVDR}; however, additional surveys are needed to confirm this trend. {T}his study highlighted challenges presented by the {WHO} methodology, such as additional costs, workload, difficulties in acquiring even small sample numbers and the necessity for better quality assurance of {HIV} testing and record keeping at antenatal clinics.},
  keywords = {},
  booktitle = {},
  journal = {{A}ntiviral {T}herapy},
  volume = {14},
  numero = {3},
  pages = {401--411},
  ISSN = {1359-6535},
  year = {2009},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00003606},
}